Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Recommendation of "Hold" from Analysts

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) have received a consensus rating of "Hold" from the seven brokerages that are presently covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $8.50.

A number of analysts have recently weighed in on the stock. HC Wainwright reissued a "buy" rating and set a $10.00 price target on shares of Regulus Therapeutics in a research report on Friday, March 14th. Canaccord Genuity Group reissued a "hold" rating and set a $11.00 price target (down previously from $28.00) on shares of Regulus Therapeutics in a research report on Wednesday, April 30th. Wall Street Zen assumed coverage on shares of Regulus Therapeutics in a research report on Sunday, May 18th. They set a "sell" rating for the company. Leerink Partners reissued a "market perform" rating and set a $7.00 price target on shares of Regulus Therapeutics in a research report on Wednesday, April 30th. Finally, Wells Fargo & Company reissued an "equal weight" rating and set a $9.00 price target on shares of Regulus Therapeutics in a research report on Thursday, May 1st.

Regulus Therapeutics Trading Down 4.0%

NASDAQ:RGLS traded down $0.33 during trading hours on Thursday, hitting $7.88. The stock had a trading volume of 17,015,722 shares, compared to its average volume of 1,002,518. Regulus Therapeutics has a 1-year low of $0.83 and a 1-year high of $8.35. The company has a market cap of $545.53 million, a PE ratio of -10.79 and a beta of 0.35. The business has a 50 day simple moving average of $6.65 and a two-hundred day simple moving average of $3.24.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.29) by $0.14. Research analysts expect that Regulus Therapeutics will post -0.88 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Preston Klassen acquired 12,000 shares of Regulus Therapeutics stock in a transaction that occurred on Tuesday, June 3rd. The shares were purchased at an average cost of $7.99 per share, for a total transaction of $95,880.00. Following the completion of the purchase, the insider now directly owns 48,055 shares of the company's stock, valued at $383,959.45. This trade represents a 33.28% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 4.35% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Regulus Therapeutics

Several large investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Regulus Therapeutics by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,345 shares of the biopharmaceutical company's stock worth $67,000 after purchasing an additional 1,644 shares during the last quarter. AQR Capital Management LLC bought a new stake in Regulus Therapeutics in the first quarter valued at $120,000. Baker BROS. Advisors LP bought a new stake in Regulus Therapeutics in the first quarter valued at $4,715,000. Velan Capital Investment Management LP lifted its stake in Regulus Therapeutics by 14.3% in the first quarter. Velan Capital Investment Management LP now owns 80,000 shares of the biopharmaceutical company's stock valued at $140,000 after buying an additional 10,000 shares during the last quarter. Finally, Driehaus Capital Management LLC bought a new stake in Regulus Therapeutics in the first quarter valued at $1,677,000. 92.38% of the stock is currently owned by institutional investors.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.